Aim of study: To compare the relationship between serum AMH and ovarian response for IVF with the GnRH antagonist protocol in patients who are carriers of FSH and/or LH receptor polymorphisms with those that are not.

Serum AMH has shown to have a high predictive capability of the ovarian response to stimulation for IVF. On the other hand, patients who are carriers of polymorphisms in the FSH and LH receptors, have shown to need higher doses of gonadotrophins for ovarian stimulation. The proportion of carriers has been described to be around 20% of the population. Nevertheless, the determination of these polymorphisms is not performed in routine practice. It is unknown if their presence affects to the relationship between serum AMH levels and ovarian response.

This is a prospective, single center, non-interventional, cohorts study.

Inclusion Criteria:

• 18-45 years of age presenting to IVF clinic
• BMI of 18-35 kg/m2
• Having been tested for serum AMH with the Elecsys assay
• Being planned to undergo ovarian stimulation cycle for IVF with the GnRH antagonist protocol
• Signed written informed consent or waiver

Exclusion Criteria:

• Current or past disease affecting ovaries, gonadotropin or sex steroid
• Current hormone therapy

Only women will undergo an ovarian stimulation for IVF treatment

Infertile Patients undergoing IVF treatments